Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy
Cell Stem Cell · 2025-07 · 32 (7) · 1087-1101.e4
DOI: 10.1016/j.stem.2025.05.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2025-07. Verfasst von Martin P Hosking und 26 weiteren Autor:innen. Beteiligte Einrichtung: Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: martin.hosking@fatetherapeutics.com. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Induced Pluripotent Stem Cells, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: martin.hosking@fatetherapeutics.com.
- Fate Therapeutics, Inc., San Diego, CA, USA.
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
- Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
- Institute for Protein Research, Osaka University, 3-2, Yamadaoka, Suita 565-0871, Osaka, Japan.
- Fate Therapeutics, Inc., San Diego, CA, USA. Electronic address: bob.valamehr@fatetherapeutics.com.
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Hosking, M. P., Shirinbak, S., Omilusik, K., Chandra, S., Kaneko, M. K., Gentile, A., Yamamoto, S., Shrestha, B., Grant, J., Boyett, M., Cardenas, D., Keegan, H., Ibitokou, S., Pavon, C., Mizoguchi, T., Ihara, T., Nakayama, D., Abujarour, R., Lee, T. T., …, & Valamehr, B. (2025). Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell Stem Cell, 32(7), 1087-1101.e4. https://doi.org/10.1016/j.stem.2025.05.007
Vancouver
Hosking MP, Shirinbak S, Omilusik K, Chandra S, Kaneko MK, Gentile A, et al. Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell Stem Cell. 2025;32(7):1087-1101.e4. doi:10.1016/j.stem.2025.05.007
BibTeX
@article{Hosking2025,
author = {Hosking, Martin P and Shirinbak, Soheila and Omilusik, Kyla and Chandra, Shilpi and Kaneko, Mika K and Gentile, Angela and Yamamoto, Susumu and Shrestha, Bishwas and Grant, Joy and Boyett, Megan and Cardenas, Demetrio and Keegan, Hannah and Ibitokou, Samad and Pavon, Carolina and Mizoguchi, Takahiro and Ihara, Tatsuya and Nakayama, Daisuke and Abujarour, Ramzey and Lee, Tom T and Clarke, Raedun and Goodridge, Jode and Peralta, Eigen and Maeda, Tatsuo and Takagi, Junichi and Arimori, Takao and Kato, Yukinari and Valamehr, Bahram},
title = {Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy},
journal = {Cell Stem Cell},
year = {2025},
volume = {32},
number = {7},
pages = {1087--1101.e4},
doi = {10.1016/j.stem.2025.05.007}
}
EUVIMED